Abstract: A dietary supplement composition provided synergistic effects of xanthorrhizol and tocotrienol on malignancies. A blend of xanthorrhizol and delta tocotrienol achieved 69% growth suppression of melanoma, exceeding the sum of individual effects. In prostate cancer, 90% growth suppression was achieved by a blend of xanthorrhizol and delta tocotrienol; however, the same 90% of growth suppression was achieved by 3-fold xanthorrhizol and 1.8-fold delta tocotrienol respectively, which indicated synergistic impact of the two agents. Mechanisms of action for the anticancer property showed synergism of xanthorrhizol and tocotrienol-mediated cancer growth suppression was attributed to cell cycle arrest, at the G1 phase of cell cycle, and apoptosis. This novel dietary supplement combination of xanthorrhizol to tocotrienol (1:1 to 10:1) may provide benefits to individuals consuming it on a regular or periodic basis.

Abstract: A dietary supplement composition provided synergistic effects of xanthorrhizol and tocotrienol on malignancies. A blend of xanthorrhizol and delta tocotrienol achieved 69% growth suppression of melanoma, exceeding the sum of individual effects. In prostate cancer, 90% growth suppression was achieved by a blend of xanthorrhizol and delta tocotrienol; however, the same 90% of growth suppression was achieved by 3-fold xanthorrhizol and 1.8-fold delta tocotrienol respectively, which indicated synergistic impact of the two agents. Mechanisms of action for the anticancer property showed synergism of xanthorrhizol and tocotrienol-mediated cancer growth suppression was attributed to cell cycle arrest, at the G1 phase of cell cycle, and apoptosis. This novel dietary supplement combination of xanthorrhizol to tocotrienol (1:1 to 10:1) may provide benefits to individuals consuming it on a regular or periodic basis.

Abstract: A composition and an associated method of treating cancer cells by impeding cancer cell growth with the composition are disclosed. The composition includes at least a first and a second HMG-CoA reductase inhibitor, wherein the total amount of the first and second HMG-CoA reductase inhibitors is effective in synergistically impeding cancer cell growth and wherein the cancer cell growth synergistic impedance from the total amount of the first and second HMG-CoA reductase inhibitors is greater than a theoretical additive effect from the combined first and second HMG-CoA reductase inhibitors. The present composition does not simultaneously contain both a tocotrienol and an ionone when the composition contains only a first and a second HMG-CoA reductase inhibitor. The method includes treating cancer cells with the claimed composition to impede cancer cell growth.

Abstract: A composition and an associated method of treating cancer cells by impeding cancer cell growth with the composition are disclosed. The composition includes at least a first and a second HMG-CoA reductase inhibitor, wherein the total amount of the first and second HMG-CoA reductase inhibitors is effective in synergistically impeding cancer cell growth and wherein the cancer cell growth synergistic impedance from the total amount of the first and second HMG-CoA reductase inhibitors is greater than a theoretical additive effect from the combined first and second HMG-CoA reductase inhibitors. The present composition does not simultaneously contain both a tocotrienol and an ionone when the composition contains only a first and a second HMG-CoA reductase inhibitor. The method includes treating cancer cells with the claimed composition to impede cancer cell growth.

Abstract: A method of and compositions for suppressing the growth of tumor cells in a patient are disclosed. In one embodiment, the method comprises treating the patient with an effective amount of an isoprenoid ether-linked compound, wherein the isoprenoid ether-linked compound comprises a first acyclic isoprenoid molecule linked via an ether linkage to a second molecule, wherein the second molecule can suppress tumor formation.

Abstract: A method of and compositions for suppressing the growth of tumor cells in a patient are disclosed. In one embodiment, the method comprises treating the patient with an effective amount of an isoprenoid ether-linked compound, wherein the isoprenoid ether-linked compound comprises a first acyclic isoprenoid molecule linked via an ether linkage to a second molecule, wherein the second molecule can suppress tumor formation.

Abstract: A method of inhibiting or preventing the growth of tumor cells is disclosed. In one embodiment, this method comprises the step of administering a compound selected from the group consisting of citracetal, citral dimethyl acetal, citral diethyl acetal, geranyl benzoate, geranyl tiglate, geranyl anthranilate, farnesyl benzoate, farnesyl anthranilate, farnesyl tiglate, farnesyl acetate and combinations thereof to a human tumor patient, wherein the amount is effective to reduce or inhibit tumor growth by at least 50%.